[Pharmacological modulation of portal hypertension syndrome: current status and future prospects].
González García
M
M
Servicio de Gastroenterología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, España.
Albillos Martínez
A
A
D018674:Adrenergic Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D005544:Forecasting; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects
D018674:Adrenergic Antagonists; D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D020030:Nitric Oxide Donors